The impressive €1.35bn ($1.5bn) sum that Forbion raised recently for its two newest funds demonstrates institutional investor belief in the sector, the European venture capital firm said, even while many public and private biotechs struggle as funding dries up.
Headquartered in Naarden, the Netherlands, and Munich, Germany, the European life sciences VC firm has just closed its Forbion Ventures...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?